Gupta 1997.

Methods	Design: randomised, placebo‐controlled, 3‐armed trial
Participants	Number assigned: 60 adults and elderly (macrolide (3‐day course) n = 28, macrolide (6‐day course) n = 12, placebo n = 20) Age in years (mean ± SD): macrolide (both arms): 58 ± 7, placebo: 60 ± 9 Setting: secondary care
Interventions	Indication: male survivors of myocardial infarction Type of macrolide: azithromycin Route: per oral Dose per day: 500 mg Duration of treatment: arm 1: 3 days, arm 2: 6 days Total treatment dose: arm 1: 1500 mg, arm 2: 3000 mg
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: yes Adverse events ascertainment: unclear Adverse events: data reported (note: do not report on "common adverse events") Antimicrobial resistance: not reported Death: data reported
Funding sources	Supported by the British Heart Foundation. Authors acknowledge supplying company (Pfizer Ltd).
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not described.
Allocation concealment (selection bias)	Unclear risk	Allocation not described.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Placebo and azithromycin supplied by the same company. However, unclear if placebo matched the single course of azithromycin (3 days) or the 2 courses (2 x 3 days).
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Only report on objective outcomes (death/myocardial infarction) not influenced by blinding.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts.
Selective reporting (reporting bias)	High risk	Adverse events stated as an outcome. Unclear ascertainment. Report on outcomes for the 2 treatment regimens as 1 group and do not report on common adverse events.
Other bias	Low risk	None were identified.